==== Front Front Immunol Front Immunol Front. Immunol. Frontiers in Immunology 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2020.615755 Immunology Correction Corrigendum: Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation Han Jin-Hwan Cai Mingmei Grein Jeffery Perera Samanthi Wang Hongmei Bigler Mike Ueda Roenna Rosahl Thomas W. Pinheiro Elaine LaFace Drake Seghezzi Wolfgang Williams Sybil M. Genther * Merck & Co. Inc., Kenilworth, NJ, United States Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland *Correspondence: Sybil M. Genther Williams, sybil_williams@merck.com This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology 18 11 2020 2020 18 11 2020 11 61575509 10 2020 20 10 2020 Copyright © 2020 Han, Cai, Grein, Perera, Wang, Bigler, Ueda, Rosahl, Pinheiro, LaFace, Seghezzi and Williams2020Han, Cai, Grein, Perera, Wang, Bigler, Ueda, Rosahl, Pinheiro, LaFace, Seghezzi and WilliamsThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.A Corrigendum on Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation By Han J-H, Cai M, Grein J, Perera S, Wang H, Bigler M, Ueda R, Rosahl TW, Pinheiro E, LaFace D, Seghezzi W and Williams SMG. Front. Immunol. (2020) 11:573405. doi: 10.3389/fimmu.2020.573405 TIGITFcγRmyeloid cellscombination cancer immunotherapycostimulatory moleculesimmune checkpoint blockade ==== Body In the original article, there was a mistake in Figure 6 as published. While upgrading the figure with a high resolution for publication, the “on-figure” legend describing each experimental group was depicted inconsistently from the rest of the article. The corrected Figure 6 appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated. Figure 6 Enhanced immune activation in tumors by anti-PD-1 can be achieved only when anti-TIGIT antibody has a functional Fc. (A–I) In order to gain molecular insights of anti-PD-1 and anti-TIGIT combination for anti-tumor responses, anti-PD-1 in the presence or absence of anti-TIGIT with mIgG1* or mIgG2a isotype were therapeutically treated in CT26 tumor-bearing mice. Four days after the second dose of each group (n = 10 per group), all the tumors were isolated and processed for real-time PCR. Relative gene expression profile of (A) CD45, (B) CD3+, (C) CD11b, (D) CD3+/CD11b ratio, (E) CD8b, (F) Foxp3, (G) IFN-g, (H) Perforin, and (I) Granzyme B. (J, K) In an independent experiment, indicated antibody regimen were injected to CT26 tumor-bearing mice every 4 days. The whole tumors were harvested untreated (day 0), 2 days after first injection (day 2), 4 days after first injection (day 4), 2 days after second injection (day 6), and 4 days after second injection (day 8). Each symbol represents average and standard error of 10 tumors from each group at each time point for the analysis of (J) Perforin and (K) Granzyme B. Orange arrow heads indicate the time points of antibody treatments. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.005; ****p < 0.001.